Author Archives : Birgit Rogell

Home  >>  Author : Birgit Rogell

Jetzt bewerben! Innovationspreis der BioRegionen 2018

On Januar 8, 2018, Posted by , In Allgemein, With Kommentare deaktiviert für Jetzt bewerben! Innovationspreis der BioRegionen 2018

Bewerbungsfrist: 18. Februar Ihre Erfindung hat Innovationskraft und Marktpotenzial? Bewerben Sie sich um einen von drei Preisen in Höhe von jeweils 2.000 € und die Aufmerksamkeit für Ihre richtungsweisende Erfindung bei den Deutschen Biotechnologietagen im April 2018 in Berlin. Der Arbeitskreis der BioRegionen Deutschlands zeichnet zum 11. Mal herausragende Ideen aus…

Merck: FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma

On Januar 8, 2018, Posted by , In Allgemein, With Kommentare deaktiviert für Merck: FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma

Second Breakthrough Therapy Designation for avelumab in hard-to-treat cancer Renal cell carcinoma, the most common form of kidney cancer, has a poor prognosis in advanced stage1,2 Javelin Renal clinical development program is ongoing, including Phase III first-line study Darmstadt, Germany, and New York, US, December 21, 2017 – Merck and…

Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas

On Januar 8, 2018, Posted by , In Allgemein, With Kommentare deaktiviert für Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment Companies aim to develop jointly-branded clinical decision support software for faster, more accurate, more confident decision-making, enabling earlier diagnosis and individualised treatment Partnership will apply advanced analytics to in-vivo data from GE’s…

BIOCRATES Life Sciences AG Acquires Metanomics Health GmbH to Create a New Global Leader in Metabolomics and Early Disease Detection

On Januar 8, 2018, Posted by , In Allgemein, With Kommentare deaktiviert für BIOCRATES Life Sciences AG Acquires Metanomics Health GmbH to Create a New Global Leader in Metabolomics and Early Disease Detection

Innsbruck, Austria – January 3rd, 2018 – BIOCRATES Life Sciences AG, a global leader in targeted metabolomics, announced today the acquisition of Metanomics Health GmbH. Metanomics Health is a metabolomics biomarker development and healthcare services specialist based in Berlin, Germany. At the same time, the company is closing a significant…

Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases

On Januar 8, 2018, Posted by , In Allgemein, With Kommentare deaktiviert für Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases

New partnership will focus on discovering and developing novel treatment options for Crohn’s disease and Ulcerative colitis Orally available novel Locked Nucleic Acid (LNA) oligonucleotides technology at the core Ingelheim, Germany – 19 December, 2017 – Boehringer Ingelheim today announced a collaborative agreement with Roche, focusing on the discovery and…

DKFZ: Levels of DNA tags characterize rare type of blood cancer

On Januar 8, 2018, Posted by , In Allgemein, With Kommentare deaktiviert für DKFZ: Levels of DNA tags characterize rare type of blood cancer

Not only genetic changes but also certain DNA tags play a role in the development of cancer. Scientists at the German Cancer Research Center (DKFZ) have discovered that leukemia of a specific type is extremely difficult to treat if the cancer cells contain very high levels of a certain type…

Logistik- und SAP-Kompetenz aus einer Hand: ParCon wird Teil von io-consultants

On Januar 8, 2018, Posted by , In Allgemein, With Kommentare deaktiviert für Logistik- und SAP-Kompetenz aus einer Hand: ParCon wird Teil von io-consultants

Heidelberg, 02.01.2018. Seit 1. Januar 2018 ist der SAP-Experte ParCon Consulting mit seinen Niederlassungen in Leonberg/Stuttgart und Berlin Teil des Beratungs- und Planungsunternehmens io-consultants mit Hauptsitz in Heidelberg. io-consultants baut dadurch seine Kompetenzen im Bereich SAP-Beratung aus und setzt ein deutliches Signal für weiteres Wachstum. Schon heute vereint io-consultants als…

DKFZ:Molecular super enhancers: A new key for targeted therapy of brain cancer in children

On Dezember 31, 2017, Posted by , In Allgemein, With Kommentare deaktiviert für DKFZ:Molecular super enhancers: A new key for targeted therapy of brain cancer in children

Ependymoma refers to a heterogeneous group of cancers that can occur at any age and is one of the most common types of brain cancer in children. The genetic causes for its development are largely unknown and there are no targeted treatments to date. Scientists from the „Hopp Children’s Cancer…

Roche: FDA approves Roche’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer

On Dezember 31, 2017, Posted by , In Allgemein, With Kommentare deaktiviert für Roche: FDA approves Roche’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer

Accelerated approval of Perjeta for neoadjuvant use also converted to full approval Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) has approved Perjeta® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast…

Roche: European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer

On Dezember 31, 2017, Posted by , In Allgemein, With Kommentare deaktiviert für Roche: European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer

Alecensa provides a new treatment option for people with newly diagnosed ALK-positive NSCLC Approval based on phase III ALEX data showing Alecensa reduced the risk of disease progression or death by more than half versus crizotinib Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has…